As of 2026-03-25, the EV/EBITDA ratio of Apellis Pharmaceuticals Inc (APLS) is 39.31. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Apellis's latest enterprise value is 2,235.07 mil USD. Apellis's TTM EBITDA according to its financial statements is 56.85 mil USD. Dividing these 2 quantities gives us the above Apellis EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 26.6x | 16.0x |
| Forward P/E multiples | 18.3x - 35.0x | 26.8x |
| Fair Price | 6.25 - 18.15 | 10.59 |
| Upside | -64.4% - 3.3% | -39.7% |
| Date | EV/EBITDA |
| 2026-03-23 | 39.31 |
| 2026-03-20 | 38.50 |
| 2026-03-19 | 40.21 |
| 2026-03-18 | 40.03 |
| 2026-03-17 | 42.12 |
| 2026-03-16 | 42.24 |
| 2026-03-13 | 42.39 |
| 2026-03-12 | 41.16 |
| 2026-03-11 | 43.38 |
| 2026-03-10 | 43.97 |
| 2026-03-09 | 44.76 |
| 2026-03-06 | 44.93 |
| 2026-03-05 | 45.11 |
| 2026-03-04 | 44.46 |
| 2026-03-03 | 45.14 |
| 2026-03-02 | 46.35 |
| 2026-02-27 | 46.94 |
| 2026-02-26 | 48.47 |
| 2026-02-25 | 47.97 |
| 2026-02-24 | 49.57 |
| 2026-02-23 | 50.33 |
| 2026-02-20 | 49.90 |
| 2026-02-19 | 51.07 |
| 2026-02-18 | 49.72 |
| 2026-02-17 | 48.31 |
| 2026-02-13 | 48.60 |
| 2026-02-12 | 49.39 |
| 2026-02-11 | 49.97 |
| 2026-02-10 | 50.58 |
| 2026-02-09 | 51.14 |
| 2026-02-06 | 52.62 |
| 2026-02-05 | 50.53 |
| 2026-02-04 | 51.86 |
| 2026-02-03 | 52.24 |
| 2026-02-02 | 51.14 |
| 2026-01-30 | 50.58 |
| 2026-01-29 | 51.64 |
| 2026-01-28 | 51.68 |
| 2026-01-27 | 48.85 |
| 2026-01-26 | 49.25 |
| 2026-01-23 | 48.71 |
| 2026-01-22 | 49.27 |
| 2026-01-21 | 46.91 |
| 2026-01-20 | 45.83 |
| 2026-01-16 | 44.64 |
| 2026-01-15 | 45.97 |
| 2026-01-14 | 45.52 |
| 2026-01-13 | 47.77 |
| 2026-01-12 | 51.97 |
| 2026-01-09 | 61.19 |